Exelixis remains dedicated to serving your needs and those of your patients. While the conference is assuming a virtual format this year, our commitment to patient care has not changed. Our team will continue to provide support to you and your patients in these challenging times. To ensure you have the latest clinical data, including links to our pivotal trial publications, and important information about the support materials below, visit our website.
Contact:
Suzy Imel
E-mail - simel@exelixis.com
David Schmahl
E-mail - dschmahl@exelixis.com
CABOMETYX® (cabozantinib) Resources »
Exelixis Access Services® (EASE) »
Full Prescribing Information »
Dosing and Administration Guide »
